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Abstract
The question of whether p73 is a tumor suppressor gene, is not yet answered with full confidence.
The lack of spontaneous tumor formation in p73 null mice and infrequent p73 mutations seen in a
variety of cancers analyzed would straightaway negate its role as a primary tumor suppressor gene.
However, accumulating evidence suggest that p73 gene and its target genes are hypermethylated
in the cancer of lymphoid origin. Here I discuss some facts and thoughts that support the idea that
p73 could still be a tumor suppressor gene. The tumor suppressor network in which p73 appears
to be a participant involves E2F1, JunB, INK4a/p16, ARF/p19, p57kip2 and BRCA1. Knock out of
each gene in E2F-1-p73-JunB-p16INK4a network of tumor suppressor proteins result in lymphoma/
leukemia formation. Further, I tried to explain why lymphomas are not seen in p73 null mice and
why p73 gene is not prone to frequent mutation.
Background
p73 is a structural and functional homologue of the
tumor suppressor, p53. Knock out studies suggest that
p73 null mice do not produce spontaneous tumor forma-
tion even after two years. However, it appears that p73
shares the properties of the tumor suppressor p53. It func-
tions more like its counterpart, p53, when it is over-
expressed, it promotes growth inhibition or apoptosis.
Evidence in favor of p73 as a main player in the 
network of tumor suppressors
1. The p73 gene was methylated in 94% cases of natural
killer cell lymphomas, a frequency that is the highest
known for any human malignancy[1]. In the NK cell lym-
phoma line NK92, p73 was also completely methyl-
ated(figure 1), and the p73 transcript was correspondingly
not detectable by quantitative polymerase chain reaction
[2,3]. Treatment of the cell line with 5-azacytidine, a
demethylation reagent, led to demethylation of the p73
promoter and reinduction of p73 gene expression. These
results suggest the following: (a)Promoter CpG methyla-
tion might be an important mechanism in suppressing
p73 gene expression in NK cells. (b) p73 can be a tumor
suppressor in NK cells.
2. Epigenetic silencing mechanism has been shown to
attenuate the expression of p73 in lymphoid cells but not
in other tumors. p73 mutations seem to be infrequent,
but some tumors do show LOH (20–60%). Interestingly,
lymphoid tumors are not prone to LOH[4]. Genomic
structure analysis of p73 promoter has found regions
enriched in CpG islands, unlike p53 gene promoter. This
could be one of the reasons why p73 is more prone to
DNA methylation mechanisms, unlike p53. Aberrant
methylation of p73 promoter has been detected in leuke-
mia and lymphoma but not in blood cells(figure 1), sup-
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porting the possibility that appropriate methylation status
of the CpG islands in the promoter region may play a cru-
cial role in the downregulation of p73 gene expression.
Unlike the p53 gene promoter, the human p73 gene pro-
moter contained a putative TATA-box, and did not exhibit
any extended homology to the p53 gene. Two CpG islands
were located in the 5' upstream region. Transient transfec-
tion assays using progressive truncations of the p73 pro-
moter showed that deletion from -119 to +19 relative to
exon 1 resulted in a 13- to 20-fold reduction in the p73
promoter activity, suggesting that the elements for basal
promoter activity exist in this region, where in putative
Sp1, AP-2 and Egr-1, 2, 3 sites are located and CpG dinu-
cleotides are especially concentrated[5].
3. It has been shown recently that promoter methylation
of at least one tumor suppressor gene was present in 26/
28 (92%) of the intraductal papillary mucinous neo-
plasms (IPMNs)[6]. The cell cycle control genes, p16 and
p73, were methylated frequently (>50%) in both non-
invasive and invasive tumors[7]. Pancreatic cancer is par-
ticularly resistant to apoptosis induced by antineoplastic
agents, which is partly attributable to the lack of func-
tional p53. However, it has been shown that E2F1 in com-
bination with the most clinically efficient drug,
gemcitabine, resulted in a strong induction of apoptosis
independent of functional p53, whereas the effect of
either therapy alone varied between different cell lines.
Intratumoral injection of a helper-dependent adenovirus
vector expressing E2F1 plus drug treatment resulted in a
significant reduction of tumor volume[6]. The therapeutic
effect is directly correlated with the induction of the p53
homologue p73, suggesting that the recently discovered
E2F1/p73 pathway plays a critical role in cancer therapy.
Methylation mechanism is evident in cancer cells but not in normal cells Figure 1
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4. The fact that MLH-/- fibroblasts do not induce p73 in
response to cisplatin treatment indicate that MLH-1 is
upstream to p73 and it is a participant in the DNA repair
pathway [8,9]. MLH-1 has been shown to be hypermeth-
ylated in several tumors including gastric and hemotopoi-
etic origin. If MLH is an upstream regulator of p73 in
tumors (in which MLH is hypermethylated), then p73
may not be activated in these tumors in response to aber-
rant DNA damage signal(figure 1). If an upstream regula-
tor of a tumor suppressor is defective, then it is obvious
that the whole pathway leading to the induction of tumor
suppressor gene will be defective. For example, tumors in
which Chk2, an upstream regulator of p53, is mutated,
p53 mutations are infrequent.
5. JunB has been shown to be a target gene of p73-α[10].
JunB is a negative regulator of proliferation and it has
been shown to induce the transcription of p16 in fibrob-
lasts[11]. Jun B has also been shown to potentiate the
function of BRCA1, which is not only expressed in mam-
mary and ovary glands but also in T-cells as well[12] (fig-
ure 1). Jun B transgenic mice lost its expression in myeloid
lineage resulting in chronic myeloid leukemia, indicating
that JunB acts as a tumor suppressor gene in myeloid
cells[13]. Silencing of p73 expression by hypermethyla-
tion or by any other mechanisms leading to the poor
expression of the p73 protein could impair the expression
of Jun B in myeloid cells. JunB serves as a causative factor
in the development of chronic myeloid leukemia. Both
JunB and Jun D are located on human chromosome 19
p13.2, a region that may be involved in chromosomal
translocation in acute lymphocytic leukemia (ALL), acute
nonlymphocytic leukemia (ANLL) and malignant
melanoma (MEL).
6. p16 has been shown to function as a tumor suppressor
gene. Further, it has been shown that JunB, a transcrip-
tional target of p73, potentiates the expression of p16[11]
(figure 1). The existence of this pathway is evident from
the fact that overexpresssion of p16INK4a correlates with
high expression of p73[14]. Furthermore, In a group of 16
patients with acute lymphoplastic leukemia(ALL), p16
was methylated in 11.7% of patients, and p73 was meth-
ylated in 17.6% of patients. This data highlights the
importance of inactivation of p73-JunB-p16 pathway in
lymphoplastic leukemia.
7. p57Kip2 is yet another player in the tumor suppressor
network. p73-beta has been shown to transactivate
p57Kip2 expression[14]. Further it has been shown that
p57Kip2 promotes growth arrest in T-cells[15]. p57Kip1
promoter is hypermethylated in a wide variety of lym-
phoid malignancies. p57KIP2 was found to be frequently
methylated (50%) in acute lymphocytic leukemia (ALL)-
derived cell lines[16].
8. 14-3-3 sigma has been shown to be a transcriptional
target of p53 and p73 and regulates G2/M phase[17]. It
has been shown that diminished or decreased expression
of 14-3-3 sigma results in increased chemoresistance of
cancer cells[18]. Further, 14-3-3 sigma blocks Akt-medi-
ated degradation of p27Kip2 and thereby enhancing the
stability of the cell cycle inhibitor p27. Thus, p73, by
potentiating the expression of 14-3-3 sigma, increases the
chemosensitvity of drug resistant cancer cells[19]. 14-3-3
is hypermethylated in breast cancer(24 of 25 carcinomas
(96%), 15 of 18 (83%) of ductal carcinoma), 89% (17/
19) of the HCC and 26 of 60 (43%) of gastric cancers [20-
23].
9. BRCA1 appears to be a selective co-activator of 14-3-3
sigma gene transcription[24].
10. Both low E2F-1 expression and p16INK4A inactiva-
tion have been identified as independent prognostic
markers[23]. This data support a role of E2F-1 as tumor
suppressor gene in lymphoma and strongly suggest that
the RB1 and p53 pathways are important in the develop-
ment of de novo diffuse large B cell lymphoma[25].
11. More recent studies implicate p73 in TCR activation-
induced cell death (TCR-AICD), indicating that p73-alpha
could play a tumor suppressor role in T-cells[26]. p73 has
been found to be transcriptionally silenced in some lym-
phoblastic leukemias and lymphomas due to hypermeth-
ylation [27,28].
12. JunB, a transcriptional target of p73, which functions
as a tumor suppressor in myeloid cells, has been shown to
be induced by 13.4 fold in Dnmt1-/- fibroblasts, indicating
that DNMT can actively silence the expression of JunB
when it is expressed[29] (figure 2). DNMT-1 is also shown
to be a transcriptional target of c-Jun and Rb[30]. In addi-
tion, it has been shown that DNMT-1 specifically targets
E2F1-1 element containing promoters and p73 promoter
bears E2F1 responsive elements[31]. Evidently, DNMT1s
were substantially overexpressed in leukemia cells in a
leukemia type-and stage-specific manner. Up-regulated
DNMTs may contribute to the pathogenesis of leukemia
by inducing aberrant regional hypermethylation of tumor
suppressor genes such as p73, JunB, p16, p57kip2, 14-3-3
and BRCA-1.
13. c-Jun has been shown to be activated in Hodgkin's
lymphoma and anaplastic large-cell-lymphoma cell
lines[32]. AP-1 complex largely contain c-JUN. NFkappa B
is also constitutively activated in Hodgkin's lymphoma
cells. It could be that overexpressed c-Jun(AP-1 complex)
consistently silent p73 by turning on DNA methyl trans-
fereases(DNMT-1) and thereby it could contribute for the
development of lymphomas(figure 2). These data furtherMolecular Cancer 2007, 6:27 http://www.molecular-cancer.com/content/6/1/27
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suggest that p73 could behave like a tumor suppressor
gene in Non-hodgkin lymphoma and in NK cell lym-
phoma's. p73 inactivation may be involved in the patho-
genesis of both T- and B-ALLs, and that hypermethylation
is the predominant mechanism of inactivation of the p73
gene in ALL. Together, it appears that overexpressed AP-1
could silence p73 in lymphocytes.
14. p73 is shown to be a transcriptional target of E2F-
1[47]. Remarkably, E2F-1 null mice develop unusual
spectrum of tumors, indicating that E2F-1 could behave
like a tumor suppressor gene. Perhaps, E2F-1 may induce
p73 expression to prevent tumorigenesis. Interestingly,
E2F-1 null mice develop spelenomegaly and are resistant
to apoptosis. Moreover, splenic T-cells isolated from p73-
deficient mice are resistant to apoptosis induced by the
ligation of the T-cell receptors, suggesting that p73 can
also induce apoptosis in activated lymphocytes[26].
15. Overexpression of p73 has been shown to upregulate
the expression of several DNA repair proteins including
DNA-PK[33]. DNA-PKcs null mice demonstrate complete
penetrance of thymic lymphoblastic lymphomas, strongly
suggesting that DNAPK functions in mice as a T-cell
tumour suppressor. Thus, down regulation of p73 could
down regulate DNAPK expression and thereby predispose
mice to thymic lymphoma formation.
16. CCAAT/enhancer binding proteins c/EBPs-alpha has
been shown to be critical for both early myeloid commit-
ment and terminal granulocyte differentiation. Both p73
and cEBP-alpha share PPXY motif, raising a possibility
Increased AP-1 activity will upregulate DNMT-1 levels and thereby silence E2F-1, p73, JunB, p16, p57, 14-3-3 and BRCA-1  expression Figure 2
Increased AP-1 activity will upregulate DNMT-1 levels and thereby silence E2F-1, p73, JunB, p16, p57, 14-3-3 and BRCA-1 
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that both, in principle, could be regulated by a common
WW domain containing co-activators such as TAZ or YAP
to regulate myeloid or granulocite differentiation.
17. p73 has been shown to upregulate the expression of
JEM-1, which is down regulated in acute promyelocytic
leukemia[34].
18. NAD(P)H:quinone oxidoreductase 1 (NQO1) seems
to stabilize both p53 and p73, inhibition of which
reduces the levels of p53 and p73. Interestingly, disrup-
tion of the NQO1 gene in mice causes myelogenous
hyperplasia[35], indicating the absence of p73 could pos-
sibly help develop myelogenous hyperplasia.
19. Promyeolocytic leukemia(PML) has been identified as
one of the interacting proteins of p73 through the yeast
two hybrid systems[36]. Further, PML has been shown to
increase the stability and function of p73[37]. Retroviral
expression of beta-catenin, plakoglobin, or PML sup-
pressed the tumorigenicity of p53-negative human renal
carcinoma cells, thus pointing to a novel antioncogenic
response triggered by catenins that is mediated by the
induction of PML.
If indeed p73 is a tumor suppressor gene, then 
why p73 null mice failed to develop lymphoma?
Explanation 1
It has been shown that adenosine deaminase (ADA) is a
transcriptional target of p73 and p63[38,39]. Further, it
has been shown that decreased expression of ADA could
lead to increased levels of adenosine. In fact, it has been
shown that ADA deficiency could lead to thymic apopto-
sis and defective TCR signaling. Hence, I hypothesize that
p73 null mice will have high level of adenosine accumu-
lated at various sites due to low expression of adenosine
deaminase (ADA). If p73 and p63 are positive regulators
of ADA, then ADA expression will be decreased in p73/
p63 null mice that could result in increased adenosine
level in p73/p63 null mice (figure 3). It has been shown
that both adenosine and its agonists inhibit the growth of
various tumor cell types such as melanoma, colon or pros-
tate carcinoma and lymphoma [40-42]. This effect is spe-
cific and is exerted on tumor cells only. Increased
adenosine level could:(a) Prevent initiation/formation of
tumors by interfering with protein and RNA biosynthesis
and thereby inhibit proliferation. In support of this hypo-
thesis, the generalized suppression of growth is evident in
p73 null mice. This could be due to increased extra and
intra cellular levels of adenosine, as increased adenosine
could inhibit the protein and RNA synthesis and thereby
prevent tumor formation(figure 3). (b) Prevent lym-
phoma formation. (c) Potentiate the function of adenos-
ine 3a receptor, which provides anti-proliferative
signals[41]. Together, this explains why p73 null mice
failed to develop lymphoma.
Explanation 2
What I intend to propose here is that p73 may not be a pri-
mary tumor suppressor gene, like its counter part p53, but
it looks certain that it is a participant in the tumor sup-
pressor network. The p73 promoter is strongly activated in
cells expressing exogenous E2F1 and suppressed by exog-
enous Rb. E2F1 null mice develop various tumors includ-
ing lymphoma. This might suggest that E2F1 could exert
its anti-proliferative action via p73. In addition, E2F1 is
capable of activating p19ARF and thereby it can increase
the stability of p53 protein to control proliferation(figure
4). This is to say that, in the absence of p73, E2F could still
control aberrant proliferation by turning on p19/ARF and
thereby stabilizing p53. In the absence of p73 and p63,
p53 is still capable of eliciting growth arrest – but not
apoptosis – by transactivating p21 promoter[43]. This
also explains why p73 null mice failed to develop lym-
phoma. The absence of E2F-1 affects both p53 stability
and p73 expression and ARF/p19 expression. This
explains why E2F1-/- null mice develop tumors, unlike
p73 null mice.
Explanation 3
The tumor suppressor pathway in which p73 appears to
be a participant involves E2F1, JunB, p16, p19, p57kip2
and BRCA1(figure 4). Each of which can elicit anti-prolif-
erative effect on its own and in the absence of the other.
In the absence of p73, Jun B transcription could still be
transactivated by other factors. And JunB could still be
capable of transactivating p16 expression and augment
the function of BRCA1. Further, if p73 functions like its
Increased adenosine concentration down regulates various  proliferation regulating mechanisms Figure 3
Increased adenosine concentration down regulates various 
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dictator, E2F-1, then we should have seen lymphoma in
p73 null mice, but that is not the case. This can be
explained if one considers the fact that E2F-1 tumor sup-
pressor pathway or network, seems to control the expres-
sion and the stability of various tumor suppressor genes
such as p19ARF, p53, JunB, p16, BRCA, p57Kip2 etc., in
addition to p73(figure 4).
Explanation 4
The facts that TA-p73 can induce apoptosis and it is hyper-
methylated in tumors of lymphoid origin indicate that
this could function like a tumor suppressor gene. On the
other hand, accumulating evidence suggest that delta-
Np73 functions more like an oncogene [44,45]. Cancer is
a genetic disease that arises through inactivation of tumor
suppressor genes and activation of oncogenes. Removal of
both oncogene and tumorsuppressor gene may not lead
to spontaneous tumor formation. For example, this could
be analogous to a situation where removal of both
p27Kip2 (inhibitor of proliferation) and cyclin D1 (acti-
vator of proliferation) may not lead to tumor formation.
Interestingly, p73 null mice lack both TA-p73 and deltaN-
p73, perhaps this could be the reason why p73 null mice
do not develop spontaneous tumors. In fact, it appears
that p73 null fibroblasts proliferate slowly(Antonio et al.,
personal communication).
Considering these facts presented here one would not be
surprised by the fact that why p73-/- mice failed to develop
lymphoma, unlike p53 null mice.
Why do p73 mutations are infrequent in tumors?
1. p73 gene contains several alternative spliced forms,
which vary in their ability to elicit growth suppressor
response. This flexibility in function will be added factor
for modulation, rather than complete inactivation. Thus,
just by varying the expression of p73 splicing prod-
ucts(TAp73 Vs DN-p73) it can be finely regulated.
2. p73 promoter is rich in CpG rich islands, unlike p53
promoter. Thus, p73 is subject to methylation mecha-
nisms mediated inactivation rather than point mutations.
3. p73 appears to co-operate with several proto-oncogenes
such as, ras, E2F-1, cyclins (A-E), BCR-abl, and myc, there-
fore, it could be less prone to selection pressure for point
mutations unlike p53. Both p53 and p73 seem to share
upstream components especially in response to DNA
damaging drugs. p53 is mutated or its upstream/down-
stream component is altered in 80% of cancer cells. If
upstream component is altered then it may not be able to
activate p73-mediated apoptotic pathway, so it may not
perform its function effectively. MLH-1 is shown to be an
upstream regulator of p73, unlike p53. MLH-1 is hyper-
methylated in a wide variety of tumors. Thus, in the
absence of MLH-1 expression, p73 may not be activated
and respond to DNA damage signals.
4. In-vitro studies support the view that E2F1 is over-
expressed in various cell lines and it regulates prolifera-
tion, while invivo  studies suggest that it is a tumor
suppressor gene. Although knock-out studies in mice sug-
gest that E2F-1 functions as a tumor suppressor, until now
no mutation has been reported in human tumors. This
could be due to the fact that complete inactivation of E2F1
function may be deleterious to the survival of normal/
cancer cells, as E2F1 also regulates proliferation associated
genes. So, it is prudent not to anticipate any mutations in
E2F1 gene. Similarly, p73 being a direct transcriptional
target of E2F-1, it could be part of the regulatory mecha-
nisms that control proliferation signals as well. Moreover,
p73 could act as an anti-apoptotic and a pro-apoptotic
protein, depending upon the cellular context and expres-
sion pattern of p73 isoforms. Thus, p73 mutations are
infrequent.
E2F1-deficient mice have been shown to develop various
tumors including reproductive tract sarcomas, lymphoma
and lung adenocarcinoma, suggesting that it functions as
a tumor suppressor gene[46]. Subsequently, it has been
shown that JunB, a negative regulator of proliferation, is a
potential transcriptional target of the tumor suppressor
p53 homolog, p73 [9,47]. Furthermore, p73 has been
shown to be a transcriptional target of the tumor suppres-
sor gene, E2F1[48] (figure 5). Wild-type mouse embry-
onic fibroblasts showed 77% apoptosis after forced E2F1
expression, both p53-/- MEFs(expressing wild-type p73)
and  p73-/-  MEFs (expressing wild-type p53), showed
reduced apoptotic cell death after forced E2F1 expression
with 12% and 15% respectively[48]. The inability of p73-/
E2F-1-p73 tumor suppressor network Figure 4
E2F-1-p73 tumor suppressor network.Molecular Cancer 2007, 6:27 http://www.molecular-cancer.com/content/6/1/27
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- mouse embryonic fibroblasts cells to undergo, despite
the presence of wtp53, apoptosis indicate that synergistic
but independent activation signal stemming from TAp73
that co-operate with p53 to induce E2F1-triggered cell
death[48]. These findings strongly suggest that E2F1 could
exert its tumor suppressor function, at least in part, via
p73. In support of this notion, Zhu JW et al., [49] showed
that E2F1-/-E2F2+/- or E2F1-/+E2F2-/- mice developed vari-
ous tumors including T/B-cell-lymphomas, lung tumors
and myeloid hyperplasia/leukemia. Accordingly, JunB – a
transcriptional target of p73 – null mice develop chronic
myeloid leukemia(CML) like disease ref. 12(figure 5),
suggesting that JunB functions as p73's downstream target
and it functions as a tumor suppressor gene in mice. In
line with this data, it has further been shown that JunB
expression is silenced in CML by hypermethylation[50]
and it functions as a negative regulator of B-lymphoid
proliferation[51] However, on the contrary to the expecta-
tion, p73 null mice failed to develop spontaneous lym-
phoma formation even after two years[52]. By contrast,
p73 is hypermethylated in various tumors. How can we
explain this tumor paradox? It is plausible that spontane-
ous tumor formation in p73 null mice could be prevented
by a molecule(s), such as adenosine, produced in its
absence.
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